Abu Dhabi has become the first in the world to deliver Itvisma, a one-time gene therapy specifically designed to target the underlying genetic cause of spinal muscular atrophy (SMA) in patients aged two years and above.
Sheikh Khalifa Medical City (SKMC) has successfully administered this groundbreaking gene therapy, developed by Novartis, under the supervision of the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate.
The therapy had been previously approved by the UAE on November 25, positioning it among the first countries globally, after the USA, to endorse the pioneering treatment.
Designed for simplicity long-term impact, Itvisma (onasemnogene abeparvovec) replaces the missing SMN1 gene to improve motor function, reducing the need for continuous treatments required by other therapies.
Dr. Noura Khamis Al Ghaithi, Under-Secretary of DoH, stated that “this milestone reflects Abu Dhabi’s commitment to delivering world class care and strengthening its position as a global leader in healthcare driven by genomics and precision medicine."
UAE condemns hostile Iranian attack targeting Qatari vessel
UAE certifies world's first commercial air taxi vertiport
Ajman unveils AED 1.8 billion urban development roadmap
H.H. Sheikh Hamdan honours government entities for digital transformation
H.H. Sheikh Mohammed to honour 'most beautiful Quranic voices in the world'
Abu Dhabi to establish specialised court for human trafficking crimes
Dubai expands support for aspiring Arab podcasters
Mohammed Saeed appointed National Media Authority's Secretary-General
